Cxbladder extends DHB coverage

7 July 2021


CXBLADDER CONTINUES TO WIN OVER NZ PUBLIC HEALTHCARE PROVIDERS
Northland District Health Board adopts full suite of Cxbladder tests

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has reached commercial agreement with
Northland District Health Board (DHB) and Northland’s primary health entity Mahitahi Hauora for the use of
Cxbladder products. This will extend the national coverage of Cxbladder delivered through New Zealand’s
public healthcare providers.

Northland DHB covers the northernmost part of New Zealand, serving a population of over 190,000, of which
approximately one-third are Maori and with a higher than average number of people aged 50 years or older.

Northland urologists, Tony Nixon, Thigesh Naidoo and Jonathan Masters, have led the adoption process for
Cxbladder products in Northland. Under the new program, patients with blood in their urine (haematuria)
will now be referred by their primary care physician (GP) for the Cxbladder Triage test and will be able to
provide a urine specimen at their local diagnostic lab, potentially avoiding the need to travel long distances
to the urology clinic or hospital for investigation.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “This agreement highlights Cxbladder’s
reach in New Zealand and draws attention to the utility of the Cxbladder for Maori and for those in more
remote parts of New Zealand. Instead of travelling all the way to Whangarei to the hospital or waiting for a
regional urology clinic to be scheduled, patients in the Far-North can get the Cxbladder test locally under the
care of their GP thereby enabling local physicians to make timely referral decisions”

“A pilot of Cxbladder testing in the Northland region showed that more than half of patients being evaluated
for haematuria or being followed up for bladder cancer could have avoided an invasive cystoscopy procedure
altogether, based on their Cxbladder test results. This represents a positive outcome for regional people and
gains in healthcare efficiency ”.



ENDS


For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder
suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and
management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder
cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s
products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence
of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer
has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients
with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of
recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer.
Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other
Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability
of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be
warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.